IndustryCompany release

Cellectis nine-month revenue falls to $14.8M as R&D spend climbs and equity turns negative

Cellectis S.A. (CLLS) · Thu 12 Nov 2026

The gene-editing company's unaudited interim accounts show a sharp fall in revenue, higher research spending, lower cash and negative shareholders' equity at 30 September 2026.

Cellectis S.A. has filed unaudited interim financial statements for the nine months ended 30 September 2026, prepared under IAS 34, the international standard for interim financial reporting.

Revenues fell to $14.8M, compared with $62.6M in the same period a year earlier. Research and development spending moved the other way, rising to $108.8M from $69.1M.

The company's cash and current financial assets declined over the period. Shareholders' equity turned negative, at about -$17.6M. The headline for the release also cites a net loss that widened to $101.1M.

The full text of the source was not available, so this report does not cover the drivers of the revenue decline, the pipeline spending breakdown, or any company commentary on funding or outlook.

What it means for your team

  • Partners and suppliers of Cellectis may wish to review the filing for details on liquidity and funding plans, which are not covered in the summary.
  • The sharp rise in R&D spending points to heavier investment in development activity; the summary does not say which programmes drove it.
  • Teams tracking cell and gene therapy developers can use the negative equity position as a prompt to follow subsequent disclosures closely.

Company's press release (SEC filing): Cellectis S.A. ↗

Article written by VigiEye from the official source (Cellectis S.A.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →